Amantadine for olanzapine-induced weight gain: A systematic review and meta-analysis of randomized placebo-controlled trials

Therapeutic Advances in Psychopharmacology

Volumn 2, Issue 4, 2012, Pages 151-156

  Praharaj, Samir Kumar ^a   Sharma, Podila Satya Venkata Narasimha ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

Author keywords

amantadine; meta analysis; olanzapine; systematic review; weight gain

Indexed keywords

AMANTADINE; OLANZAPINE; PLACEBO;

ARTICLE; BIPOLAR I DISORDER; BODY WEIGHT; DRUG EFFECT; DRUG INDUCED DISEASE; EFFECT SIZE; HUMAN; MANTEL HAENSZEL TEST; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84998166021     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125312440441     Document Type: Article

References (29)

1. Allison D.B. Mentore J.L. Heo M. Chandler L.P. Cappelleri J.C. Infante M.C. et al. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686–1689.
2. Bahk W.M. Lee K.U. Chae J.H. Pae C.U. Jun T. Kim K.S. (2004) Open label study of the effect of amantadine on weight gain induced by olanzapine. Psychiatry Clin Neurosci 58: 163–167.
3. Baptista T. ElFakih Y. Uzcátegui E. Sandia I. Tálamo E. Araujo de Baptista E. et al. (2008) Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22: 477–495.
4. Baptista T. López M.E. Teneud L. Contreras Q. Alastre T. de Quijada M. et al. (1997) Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates. Pharmacopsychiatry 30: 43–54.
5. Baptista T. Sandia I. Lacruz A. Rangel N. de Mendoza S. Beaulieu S. et al. (2007) Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int Clin Psychopharmacol 22: 69–76.
6. Deberdt W. Winokur A. Cavazzoni P.A. Trzaskoma Q.N. Carlson C.D. Bymaster F.P. et al. (2005) Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 15: 13–21.
7. Faulkner G. Cohn T.A. (2006) Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry 51: 502–511.
8. Faulkner G. Cohn T. Remington G. (2007) Interventions to reduce weight gain in schizophrenia. Schizophr Bull 33: 654–656.
9. Fernández E. Carrizo E. Fernández V. Connell L. Sandia I. Prieto D. et al. (2010) Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin. Schizophr Res 121: 213–217.
10. Floris M. Lejeune J. Deberdt W. (2001) Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol 11: 181–182.
11. Gracious B.L. Krysiak T.E. Youngstrom E.A. (2002) Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. J Child Adolesc Psychopharmacol 12: 249–257.
12. Graham K.A. Gu H. Lieberman J.A. Harp J.B. Perkins D.O. (2005) Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 162: 1744–1746.
13. Hasnain M. Vieweg W.V. Fredrickson S.K. (2010) Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions. CNS Drugs 24: 193–206.
14. Henderson D.C. Cagliero E. Copeland P.M. Borba C.P. Evins E. Hayden D. et al. (2005) Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal modal analysis. Arch Gen Psychiatry 62: 19–28.
15. Higgins J.P. Thompson S.G. Deeks J.J. Altman D.G. (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
16. Jadad A.R. Moore R.A. Carroll D. Jenkinson C. Reynolds D.J. Gavaghan D.J. et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1–12.
17. Jefferson T. Demicheli V. Di Pietrantonj C. Rivetti D. (2006) Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev 2: CD001169.
18. Juni P. Altman D.G. Egger M. (2001) Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 323: 42–46.
19. Kluge M. Schuld A. Himmerich H. Dalal M. Schacht A. Wehmeier P.M. et al. (2007) Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double blind study. J Clin Psychopharmacol 27: 662–666.
20. Komossa K. Rummel-Kluge C. Hunger H. Schmid F. Schwarz S. Duggan L. et al. (2010) Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 3: CD006654.
21. Lieberman J.A. Stroup T.S. McEvoy J.P. Swartz M.S. Rosenheck R.A. Perkins D.O.; Clinical Antipsychotic Trials of Intervention Effectiveness et al. (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209–1223.
22. Maayan L. Vakhrusheva J. Correll C.U. (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35: 1520-1530.
23. Moher D. Liberati A. Tetzlaff J. Altman D.G., for the The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6: e1000097.
24. Nemeroff C.B. (1997) Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 58: 45–49.
25. Silver H. Geraisy N. (1996) Amantadine does not exacerbate positive symptoms in medicated, chronic schizophrenic patients: evidence from a double-blind crossover study. J Clin Psychopharmacol 16: 463–464.
26. Simon V. van Winkel R. De Hert M. (2009) Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 70: 1041–1050.
27. Stahl S.M. (1998) Neuropharmacology of obesity: my receptors make me eat. J Clin Psychiatry 59: 447–448.
28. Stauffer V.L. Lipkovich I. Hoffmann V.P. Heinloth A.N. McGregor H.S. Kinon B.J. (2009) Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. BMC Psychiatry 9: 12.
29. Sussman N. (2001) Review of atypical antipsychotics and weight gain. J Clin Psychiatry 62: 5–12.